{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AGN-199201",
    "query": {
      "intervention": "AGN-199201"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T03:41:44.962Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02197806",
      "title": "Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Presbyopia"
      ],
      "interventions": [
        {
          "name": "AGN-199201",
          "type": "DRUG"
        },
        {
          "name": "AGN-190584",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "40 Years to 55 Years"
      },
      "enrollment_count": 65,
      "start_date": "2014-07",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2015-12-03",
      "last_synced_at": "2026-09-08T03:41:44.962Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02197806"
    },
    {
      "nct_id": "NCT02131636",
      "title": "Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Erythema",
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "AGN-199201",
          "type": "DRUG"
        },
        {
          "name": "Vehicle to AGN-199201",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 440,
      "start_date": "2014-05",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-09-08T03:41:44.962Z",
      "location_count": 1,
      "location_summary": "Lynchburg, Virginia",
      "locations": [
        {
          "city": "Lynchburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02131636"
    },
    {
      "nct_id": "NCT02780115",
      "title": "A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Presbyopia"
      ],
      "interventions": [
        {
          "name": "AGN-199201 ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "AGN-190584 ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 Vehicle",
          "type": "DRUG"
        },
        {
          "name": "AGN-190584 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "40 Years to 55 Years"
      },
      "enrollment_count": 151,
      "start_date": "2016-05-26",
      "completion_date": "2017-10-31",
      "has_results": true,
      "last_update_posted_date": "2020-12-22",
      "last_synced_at": "2026-09-08T03:41:44.962Z",
      "location_count": 25,
      "location_summary": "Arcadia, California • Artesia, California • Cypress, California + 19 more",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02780115"
    },
    {
      "nct_id": "NCT02132117",
      "title": "Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Erythema",
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "Oxymetazoline HCL Cream 1.0%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle to Oxymetazoline HCL Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 445,
      "start_date": "2014-06",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-09-08T03:41:44.962Z",
      "location_count": 1,
      "location_summary": "College Station, Texas",
      "locations": [
        {
          "city": "College Station",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02132117"
    },
    {
      "nct_id": "NCT02095158",
      "title": "A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Erythema",
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "Oxymetazoline HCL Cream 1.0%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 440,
      "start_date": "2014-04",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-09-08T03:41:44.962Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02095158"
    },
    {
      "nct_id": "NCT01579084",
      "title": "Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rosacea",
        "Erythema"
      ],
      "interventions": [
        {
          "name": "AGN-199201 Formulation A",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 Formulation B",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 Formulation C",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2012-04",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-09-08T03:41:44.962Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01579084"
    },
    {
      "nct_id": "NCT02595528",
      "title": "A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Presbyopia"
      ],
      "interventions": [
        {
          "name": "AGN-199201 ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "AGN-190584 ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "AGN-190584 vehicle",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 + AGN-190584 Combination",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "40 Years to 50 Years"
      },
      "enrollment_count": 163,
      "start_date": "2016-04-29",
      "completion_date": "2017-10-18",
      "has_results": true,
      "last_update_posted_date": "2020-12-22",
      "last_synced_at": "2026-09-08T03:41:44.962Z",
      "location_count": 20,
      "location_summary": "Artesia, California • Azusa, California • Costa Mesa, California + 17 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02595528"
    },
    {
      "nct_id": "NCT01735201",
      "title": "AGN-199201 for the Treatment of Erythema With Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rosacea",
        "Erythema"
      ],
      "interventions": [
        {
          "name": "AGN-199201 Dose A",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 Dose B",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 Dose C",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 357,
      "start_date": "2012-12",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-09-08T03:41:44.962Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01735201"
    }
  ]
}